The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients.
The risk for venous thromboembolism (VTE) is high in hospitalized cancer patients, and is associated with an elevated risk for recurrent thrombosis, bleeding complications, and use of health care resources. Thromboembolism is the second leading cause of death in hospitalized cancer patients. Thromboprophylaxis with unfractionated heparin or low-molecular-weight heparins has been clinically proven to reduce the risk for VTE and improve outcomes. However, VTE prophylaxis continues to be underprescribed in cancer patients. Recognizing the clinical burden of VTE in cancer patients, the National Comprehensive Cancer Network (NCCN) recently released guidelines for VTE prevention and management. These NCCN guidelines recommend evidence-based prophylactic anticoagulant therapy for all patients admitted to hospital with a diagnosis of cancer who do not have contraindications to anticoagulant use. However, there continue to be barriers to the implementation of clinical practice guidelines and appropriate use of VTE prophylaxis. Multifaceted active educational and electronic interventions are necessary to raise awareness and reduce the burden of cancer-associated thrombosis and its attendant consequences.
James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, New York 14642, USA. alok_khorana@URMC.rochester.edu
Alok A
AA
Khorana
D000925:Anticoagulants / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D013927:Thrombosis; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000188:drug therapy; D054556:Venous Thromboembolism / Q000628:therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight